Summit Therapeutics Inc. is a biopharmaceutical company headquartered in Menlo Park, California, specializing in the discovery, development, and commercialization of novel oncology therapies. The company's mission is to address serious unmet medical needs by developing patient-, physician-, caregiver-, and societal-friendly medicinal therapies aimed at improving quality of life and increasing the potential duration of life.
Summit's lead candidate is ivonescimab (also known as SMT112 in certain regions), a bispecific antibody that simultaneously targets PD-1 and VEGF pathways. This dual mechanism aims to enhance anti-tumor immunity and inhibit tumor angiogenesis. Ivonescimab is currently undergoing multiple Phase 3 clinical trials, including HARMONi, HARMONi-3, and HARMONi-7, focusing on non-small cell lung cancer (NSCLC) and biliary tract cancer.
In December 2022, Summit entered into a strategic partnership with Akeso Inc. to in-license ivonescimab for development and commercialization in the United States, Canada, Europe, Japan, Latin America, the Middle East, and Africa. The agreement includes a $500 million upfront payment and potential milestone payments totaling up to $5 billion, along with royalties on net product sales . Additionally, Summit has collaborated with Pfizer to evaluate ivonescimab in combination with Pfizer's antibody-drug conjugates in various solid tumor settings.
Summit Therapeutics is also working with The University of Texas MD Anderson Cancer Center in a five-year collaboration to accelerate the development of ivonescimab across multiple tumor types. This partnership leverages MD Anderson's clinical infrastructure and research expertise to broaden the clinical applications of ivonescimab . With a strong pipeline and strategic collaborations, Summit is positioned to make significant advancements in oncology therapeutics.